ONCOLife Issues
Featured Articles
Trending Articles
FDA Approves Keytruda–Padcev Combo as First Perioperative Treatment for Bladder Cancer
FDA & EMA | 24 November 2025
Sevabertinib Wins FDA Approval with Strong Responses in HER2+ NSC Lung Cancer
FDA & EMA | 20 November 2025
FDA Approves Epcoritamab-bysp as the First Bispecific Antibody for Follicular Lymphoma
FDA & EMA | 19 November 2025
FDA Approves Ziftomenib as a New Targeted Option for NPM1+ Acute Myeloid Leukemia
FDA & EMA | 14 November 2025
Radioligand Therapy Pluvicto Reduces Progression Risk by 28% in mHS Prostate Cancer
ONCOLife | 5 November 2025
Lenvatinib Plus Everolimus Improves Outcomes After PD-1 Failure in Kidney Cancer
ONCOLife | 6 November 2025
Novartis Invests $23 Billion to Boost Radioligand Manufacturing Capacity in Carlsbad
Pharma | 11 November 2025
Ribociclib Extends Disease-Free Survival Beyond Treatment in HR+/HER2– Early Breast Cancer
ONCOLife | 3 November 2025
DeLLphi-303: Tarlatamab Plus Chemo Achieves 71% Response in ES Small-Cell Lung Cancer
ONCOLife | 4 November 2025
Trodelvy Emerges as Potential New Standard for First-Line Metastatic TN Breast Cancer
ONCOLife | 24 October 2025
Datroway Extends Survival by 5 Months in Metastatic Triple-Negative Breast Cancer
ONCOLife | 21 October 2025
AI Analysis of Thymic Health Predicts Immunotherapy Success, Cutting Death Risk by 44%
ONCOLife | 18 October 2025
In Vivo CAR T on the Horizon: BMS Acquires Orbital to Expand Cell Therapy Reach
Pharma
10 October 2025
AstraZeneca makes deal with Trump Admin to Cut Drug Prices 80% and Invest $50B in US
Pharma
11 October 2025
FDA Approves Libtayo as First Adjuvant Immunotherapy for High-Risk CS Cell Carcinoma
FDA & EMA
9 October 2025
FDA Approves Tecentriq–Zepzelca Combo as FL Maintenance Therapy for ES-SC Lung Cancer
FDA & EMA
3 October 2025
Dr. Eleni Lagkadinou Discusses How AbbVie Is Advancing Targeted Innovation for HT Cancers
ONCOLife
1 October 2025
FDA Approves Imlunestrant for ESR1-Mutated Metastatic Breast Cancer
FDA & EMA
27 September 2025
DESTINY-Breast05: Enhertu Outperforms T-DM1 in High-Risk HER2+ Early Breast Cancer
FDA & EMA
1 October 2025
The V Foundation and CVC Collaborate to Advance Breast Cancer Vaccine Research
ONCOLife
12 September 2025
NEJM Study Confirms Low-Dose Aspirin Halves Recurrence in Colorectal Cancer
Clinical Trials
20 September 2025
Sugary Drinks Drive Colorectal Cancer Metastasis via SORD Pathway, Study Finds
ONCOLife
20 September 2025
EMA’s CHMP Backs Subcutaneous Pembrolizumab in Head and Neck Cancer
FDA & EMA
19 September 2025